Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| D012141 | Respiratory Tract Infections NIH | 0.16 |
| D007239 | Infection NIH | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| HP:0011947 | Respiratory tract infection HPO | 0.16 |
Navigate: Correlations HPO
There is one clinical trial.
A randomized, parallel-group treatment, quadruple masked, two-arm study to assess the effectiveness of cod liver oil compared to placebo in the prevention of Covid-19 and airway infections in healthy adults. In this study, the investigators will investigate whether daily cod liver oil can prevent Covid-19 infections and reduce the severity of such infections. The investigators will also examine whether cod liver oil prevents other airway infections in healthy adults.
Description: The number of participants with first time SARS-CoV-2 positive nasopharyngeal and or pharyngeal swabs (or any other sample used for detection of current disease) analyzed by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) nucleic acid amplification test or antigen tests used by accredited Norwegian microbiology laboratories in the period from one week after the start of cod liver oil/placebo taking to the end of this period together with any of the following: A) Self-reported dyspnea and fever concurrent (within four weeks) with the positive test OR B) hospitalization caused by Covid-19 concurrent (within four weeks) with the positive test OR C) death where the Covid-19 infection was wholly or partly responsible as judged by the death certificate (see endpoint in the protocol)
Measure: Number of participants diagnosed with serious Covid-19 Time: 6 monthsDescription: The number of participants diagnosed with first time SARS-CoV-2 positive nasopharyngeal and or pharyngeal swabs (or any other sample used for detection of current disease) analyzed by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) nucleic acid amplification test or antigen tests used by accredited Norwegian microbiology laboratories from one week after the start of cod liver oil/placebo taking.
Measure: Number of participants diagnosed with New Covid-19 Time: 6 monthsDescription: Number of participants with an airway sample positive for a respiratory pathogen* (either PCR or culture). *Influenza virus (A and B), parainfluenzavirus (1,2,3), metapneumovirus, rhinovirus, coronavirus (non-SARS), Respiratory Syncytial virus, Haemophilus Influenzae, Moraxella Catharralis, Streptococcus Pneumonia, Beta-hemolytic streptococci, Mycoplasma pneumonia, Chlamydophila pneumonia, Enterovirus, Bordetella pertussis. The list can be expanded based on the analyses performed in Norwegian Microbiology laboratories.
Measure: Number of participants with laboratory confirmed respiratory tract infection Time: 6 monthsDescription: The number of episodes with any two of the following symptoms: fever, cough, nasal congestion or sore throat
Measure: Number of participants with self-reported airway infection Time: 6 monthsDescription: Number of participants hospitalized wholly or partly caused by Covid-19.
Measure: Number of participants hospitalized due to Covid-19 Time: 6 monthsDescription: Number of participants with ICU care wholly or partly caused by Covid-19.
Measure: Number of participants in Intensiv Care Unit (ICU) caused by Covid-19 Time: 6 monthsDescription: Number of participants with any admissions to hospital based on the Norwegian Patient Registry data.
Measure: Number of participants with any admissions to hospital Time: 6 monthsDescription: An airway sample positive for a respiratory pathogen* (either PCR or culture) in the period from one week after the start of cod liver oil/placebo taking to the end of this period. *Influenza virus (A and B), parainfluenzavirus (1,2,3), metapneumovirus, rhinovirus, coronavirus (non-SARS), Respiratory Syncytial virus, Haemophilus Influenzae, Moraxella Catharralis, Streptococcus Pneumonia, Beta-hemolytic streptococci, Mycoplasma pneumonia, Chlamydophila pneumonia, Enterovirus, Bordetella pertussis. The list can be expanded based on the analyses performed in Norwegian Microbiology laboratories.
Measure: Infection with each of the mentioned pathogens Time: 6 monthsDescription: Based on The Norwegian Reimbursement Database
Measure: Number of visits at GP for infections Time: 6 monthsDescription: Based on The Norwegian Reimbursement Database
Measure: Number of visits at GP Time: 6 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incidence of Cardiovascular disease Time: 6 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incidence of Cardiovascular disease Time: 30 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incidence of cardiovascular mortality Time: 6 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incidence of cardiovascular mortality Time: 30 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incidence of cancer Time: 6 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incidence of cancer Time: 30 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incidence of cancer mortality Time: 6 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incidence of cancer mortality Time: 30 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: All-cause mortality Time: 6 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: All-cause mortality Time: 30 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incidence of fracture of the hip or forearm Time: 6 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incidence of fracture of the hip or forearm Time: 30 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incident dementia Time: 6 monthsDescription: Based on self-reporting and Norwegian Registries
Measure: Incident dementia Time: 30 monthsDescription: The number of participants with first time SARS-CoV-2 positive nasopharyngeal and or pharyngeal swabs (or any other sample used for detection of current disease) analyzed by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) nucleic acid amplification test or antigen tests used by accredited Norwegian microbiology laboratories in the period from one week after the start of cod liver oil/placebo taking to the end of this period together with any of the following: A) Self-reported dyspnea and fever concurrent (within four weeks) with the positive test OR B) hospitalization caused by Covid-19 concurrent (within four weeks) with the positive test OR C) death where the Covid-19 infection was wholly or partly responsible as judged by the death certificate (see endpoint in the protocol)
Measure: Number of participants diagnosed with serious Covid-19 Time: 12 monthsDescription: The number of participants diagnosed with first time SARS-CoV-2 positive nasopharyngeal and or pharyngeal swabs (or any other sample used for detection of current disease) analyzed by reverse transcriptase quantitative polymerase chain reaction (RT-qPCR) nucleic acid amplification test or antigen tests used by accredited Norwegian microbiology laboratories from one week after the start of cod liver oil/placebo taking.
Measure: Number of participants diagnosed with new Covid-19 Time: 12 monthsDescription: An airway sample positive for a respiratory pathogen* (either PCR or culture). *Influenza virus (A and B), parainfluenzavirus (1,2,3), metapneumovirus, rhinovirus, coronavirus (non-SARS), Respiratory Syncytial virus, Haemophilus Influenzae, Moraxella Catharralis, Streptococcus Pneumonia, Beta-hemolytic streptococci, Mycoplasma pneumonia, Chlamydophila pneumonia, Enterovirus, Bordetella pertussis. The list can be expanded based on the analyses performed in Norwegian Microbiology laboratories.
Measure: Laboratory confirmed respiratory tract infection Time: 12 monthsDescription: The number of episodes with any two of the following symptoms: fever, cough, nasal congestion or sore throat
Measure: Self-reported airway infection Time: 12 monthsDescription: Number of participants with self-reported adverse events
Measure: Number of participants with self-reported cod liver oil related adverse events Time: 12 monthsDescription: Number of participants hospitalized for major diseases or death in the cod liver oil versus placebo group in Norwegian registries
Measure: Number of participants with cod liver oil related adverse events Time: 12 monthsAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports